Irma Meijerman

Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell lines

Esther Brandon, Tessa M. Bosch, Maarten J. Deenen et al. · Toxicology and Applied Pharmacology · 2005 · 112 citations

Medicine, Pharmacokinetics, Pharmacology +17

PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line

Stefan Harmsen, Irma Meijerman, C. L. Febus et al. · Cancer Chemotherapy and Pharmacology · 2009 · 105 citations · Full text

Medicine, Oncology, Pharmacology +12

Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor

Stefan Harmsen, Irma Meijerman, Jos H. Beijnen et al. · Cancer Chemotherapy and Pharmacology · 2008 · 93 citations · Full text

Medicine, Oncology, Pharmacology +17

The Effect of St John’s Wort on the Pharmacokinetics of Docetaxel

Andrew K.L. Goey, Irma Meijerman, Hilde Rosing et al. · Clinical Pharmacokinetics · 2013 · 66 citations

Pharmacy, Pharmacokinetics, Pharmacology +5

Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status

Tom Schalekamp, Marloes M. Oosterhof, E VANMEEGEN et al. · Clinical Pharmacology & Therapeutics · 2004 · 61 citations

Medicine, Genetics, Pharmacology +17